Thanks for the info - but what's your point? In layman's terms please.
"k p Collins" <kpaulc@[----------]earthlink.net> wrote in message
news:D9JMb.5155$q4.1649 at newsread3.news.atl.earthlink.net...
> If one takes action that indiscriminantly 'blocks' the
> normal functions of zinc and copper ions, then one
> is blocking more than the roles that these ions play
> in the formation of 'plaques'.
>> In my view, Alsheimer's results from larger dynamics
> in which the 3-D energydynamics that 'normally'
> focus selective addressing of the DNA-RNA are
> prematurely terminated, yielding incompletely-
> formed 'protein'-scraps that are what the "plaques"
> are.
>> This's a classic instance of 'inability' to achieve
> sufficient TD E/I-minimization in which molecular-
> 'level' 3-D energydynamics are prematurely-
> terminated be-cause TD E/I-minimization does
> not procede to 'completion' - it's a "pawling" [AoK,
> Ap5]deficit within the TD E/I-minimization mech-
> anisms as they are discussed in AoK.
>> The treatment that will work will re-establish the
> normal DNA-RNA-tuning durations by re-establish-
> ing the 'normal' functional-scopes of TD E/I-mini-
> mization.
>> Look for the "pawling" deficit, and its causes.
>> Blanket-blocking of this or that ion's action will
> not work.
>> k. p. collins
>> "Hua Kul" <gmp at adres.nl> wrote in message
> news:3da4c6e5.0401121755.7cecf1af at posting.google.com...> > (The following is from the thread
> >
>http://groups.google.com/groups?hl=en&lr=&ie=UTF-8&oe=UTF-8&threadm=afe2faf1
>.0308141829.d00f6d2%40posting.google.com&rnum=2&prev=/groups%3Fhl%3Den%26lr%
>3D%26ie%3DUTF-8%26oe%3DUTF-8%26q%3Dclioquinol%26btnG%3DGoogle%2BSearch%26met
> a%3Dgroup%253Dsci.life-extension)
> >
> > > Tim Tyler (tim at tt1.org)
> > > Subject: Re: Copper & Alzheimer's Disease
> >
> > > A report of a previous study:
> >
> > > ``Research teams at Harvard Medical School, the University of
Melbourne,
> > > and Prana Biotechnology Ltd in Australia are working collaboratively
> on
> > > giving Alzheimer's-prone mice copper chelators, substances that sop
up
> > > metals and eliminate them from the body. These new metal-binding
drugs
> > > effectively "melted" the amyloid plaques in living mice in as little
> as
> > > nine weeks, and are now in clinical trials with Alzheimer's
> > > patients. Results of the first of these drugs, clioquinol, should be
> > > known within 12 months, and further trials of this approach are
> > > currently in preparation.''
> >
> > > - http://www.infoaging.org/d-alz-9-r-metals.html> > > --
> > __________
> > > |im |yler http://timtyler.org/tim at tt1.org> >
> >
> > Here is a small study indicating clioquinol virtually halted
> > progression of moderate AD in humans.
> >
> > ====================================================================
> > 1: Arch Neurol. 2003 Dec;60(12):1685-91. Related Articles, Links
> >
> > Comment in:
> > Arch Neurol. 2003 Dec;60(12):1678-9.
> >
> > Metal-protein attenuation with iodochlorhydroxyquin (clioquinol)
> > targeting Abeta amyloid deposition and toxicity in Alzheimer disease:
> > a pilot phase 2 clinical trial.
> >
> > Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor
> > L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C,
> > Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE,
> > Masters CL.
> >
> > Departments of Pathology, The University of Melbourne, The Mental
> > Health Research Institute of Victoria, Parkville, Victoria, Australia.
> >
> > BACKGROUND: Alzheimer disease (AD) may be caused by the toxic
> > accumulation of beta-amyloid (Abeta). OBJECTIVE: To test this theory,
> > we developed a clinical intervention using clioquinol, a
> > metal-protein-attenuating compound (MPAC) that inhibits zinc and
> > copper ions from binding to Abeta, thereby promoting Abeta dissolution
> > and diminishing its toxic properties. METHODS: A pilot phase 2
> > clinical trial in patients with moderately severe Alzheimer disease.
> > RESULTS: Thirty-six subjects were randomized. The effect of treatment
> > was significant in the more severely affected group (baseline
> > cognitive subscale score of the Alzheimer's Disease Assessment Scale,
> > >/=25), due to a substantial worsening of scores in those taking
> > placebo compared with minimal deterioration for the clioquinol group.
> > Plasma Abeta42 levels declined in the clioquinol group and increased
> > in the placebo group. Plasma zinc levels rose in the
> > clioquinol-treated group. The drug was well tolerated. CONCLUSION:
> > Subject to the usual caveats inherent in studies with small sample
> > size, this pilot phase 2 study supports further investigation of this
> > novel treatment strategy using a metal-protein-attenuating compound.
> >
> > Publication Types:
> > Clinical Trial
> > Clinical Trial, Phase II
> > Randomized Controlled Trial
> >
> > PMID: 14676042 [PubMed - indexed for MEDLINE]
> >
> >
>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ui
> ds=14676042&dopt=Abstract
> >
> > ======================================================================
> >
> > Here'a an article on the study.
> >
> > ===============================================================
> > Drug used to treat athlete's foot 'slows down Alzheimer's'
> > By Michael Day and Martyn Halle
> > (Filed: 11/01/2004)
> >
> >
> > A drug that is used in the treatment of athlete's foot could be used
> > to treat Alzheimer's disease, according to a new study by British
> > doctors.
> >
> >
> > Iris Murdoch, who died in 1999, and her husband John Bayley
> > The study, by a team from University College, London, found that
> > clioquinol, a drug that is also used to treat ear infections and
> > indigestion, can almost halt the progression of Alzheimer's.
> >
> > It discovered that clioquinol, which was developed 100 years ago, is
> > able to absorb the zinc and copper atoms that concentrate in the
> > brains of Alzheimer's sufferers before dementia sets in.
> >
> > Doctors believe that by absorbing these atoms, clioquinol can arrest
> > the onset of dementia, potentially helping thousands of people.
> >
> > Dr Craig Ritchie, a psychiatrist at UCL and a Medical Research Council
> > research fellow who led the trial, said that the results were "very
> > exciting".
> >
> > "The patients on this trial had Alzheimer's that was mild to moderate,
> > but there was very little change in their brains once they had started
> > treatment," he said.
> >
> > "This drug could give your mind a chance to stay healthy as long as
> > your body does. Particularly for patients who get this terrible
> > disease in middle age, we need better treatments."
> >
> > The study was prompted by research at Melbourne University in
> > Australia and Harvard University in the United States, which found
> > that clioquinol could prevent zinc from building up on the surface of
> > the brain.
> >
> > Academics from the universities speculated that by blocking zinc they
> > could halt, and possibly reduce, the brain damage that causes
> > Alzheimer's victims to lose their memory.
> >
> > To test their theory, the UCL doctors tested 13 Alzheimer's patients,
> > giving them clioquinol over a nine-month period, and 13 other
> > Alzheimer's sufferers who were given a placebo.
> >
> > The results, published in the Archives of Neurology, show that
> > patients given clioquinol retained significantly more mental capacity
> > than those who received the placebos. Dr Ritchie said that the
> > patients taking clioquinol experienced a decline in their mental
> > faculties of just 1.4 per cent.
> >
> > "You would normally see a drop of four points or more in someone with
> > Alzheimer's over the period of time we treated these patients," he
> > added. "For those taking the placebo, their mental decline was 8.9 per
> > cent. It's a very large gap and indicated that the drug was working."
> >
> > Alzheimer's affects one in 10 people over the age of 65, and almost
> > half of those aged 85 and over.
> >
> > The protective effect of clioquinol appears to be nearly twice as
> > great as that of the latest generation of Alzheimer's drugs, such as
> > donepezil, which are expensive and not always widely available.
> >
> > A survey by Pfizer, the drug company, revealed last week that the
> > availability of treatments, which cost up to £100 a month, varied
> > sharply across Britain. In the worst area, Lothian in Scotland, less
> > than £1 a head was spent on these drugs in the over-65 population
> > compared with more than £10 a head in Northern Ireland.
> >
> > Clioquinol should be much cheaper because it is no longer protected by
> > a patent.
> >
> > Prana Technology, an Australian drug firm, provided clioquinol for the
> > first small trial. Larger trials of the drug are expected to start
> > shortly and will include British patients.
> >
> > Dr Ritchie said that animal studies had suggested that the drug might
> > even reverse the progress of the dementia - something that current
> > treatments are unable to do.
> >
> > "We know that in mice the disease was reversed. Everyone is excited
> > but this was only a small trial and we have to do a larger trial. We
> > think this drug will produce the same results in extended trials with
> > humans. If we can get to them early, we might be able to treat
> > patients and leave them with very little damage to their brain."
> >
> > One fear over the long-term use of clioquinol is that it may damage
> > peripheral nerves and the nerves in the eye. Dr Ritchie said his team
> > found no evidence of this during their trial.
> >
> > Dr Susanne Sorensen, the head of research at the Alzheimer's Society,
> > said: "The UCL research suggests that there may be a novel use for
> > this already existing drug in the treatment of Alzheimer's disease.
> > But the trial is limited in its scale and we believe it would be
> > valuable to see a larger scale trial.
> >
> > "The potential for new drugs that may interfere with or revert the
> > progression of Alzheimer's disease gives hope to people with dementia
> > and their carers."
> >
> > The plight of sufferers and their carers was brought home to millions
> > two years ago when the film biography of the novelist Iris Murdoch was
> > showered with awards for its touching and realistic portrayal of the
> > writer's dementia.
> >
> >
>http://news.telegraph.co.uk/news/main.jhtml?xml=/news/2004/01/11/nalz11.xml&
> sSheet=/news/2004/01/11/ixhome.html/news/2004/01/11/nalz11.xml
> >
> > =====================================================================
> >
> >
> > --Hua Kul
> > huaREMOVEkul at hotmail.com>>
